Return to homepagePandemic Pact

Development of novel pharmacotherapy to prevent development of severe conditions in patients with COVID-19 and to improve long-term prognosis, and its companion diagnostics

  • Funded by Japan Agency for Medical Research and Development (AMED)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Funder

    Japan Agency for Medical Research and Development (AMED)

  • Principal Investigator

    Chief executive officer Hiroshi NAGABUKURO

  • Research Location

    Japan

  • Lead Research Institution

    ARTham Therapeutics Inc.

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract